Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 4/20 | 0.43 |
| ▸ | JAK1 | P23458 | 4/20 | 0.43 |
| ▸ | CHRNB2 | P17787 | 6/20 | 0.35 |
| ▸ | CHRNB4 | P30926 | 6/20 | 0.35 |
| ▸ | CHRNA3 | P32297 | 6/20 | 0.35 |
| ▸ | CHRNA4 | P43681 | 6/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.33 |
| ▸ | PIM1 | P11309 | 4/20 | 0.33 |
| ▸ | PIM2 | Q9P1W9 | 4/20 | 0.33 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.33 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.30 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.30 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31756438 | 1.00 | JAK2 (0.43) | JAK2JAK1CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL34467918 | 0.94 | JAK2 (0.39) | JAK2JAK1CHRNB2CHRNB4CHRNA3 | |
| Hydrochloric Acid SCHEMBL34468017 | 0.93 | JAK2 (0.38) | JAK2JAK1CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL34467973 | 0.83 | JAK2 (0.37) | JAK2JAK1CHRNB2CHRNB4CHRNA3 | |
| Hydrochloric Acid SCHEMBL31755992 | 0.82 | JAK2 (0.38) | JAK2JAK1CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL34467950 | 0.80 | SMN1; SMN2 (0.34) | — | |
| SCHEMBL34467965 | 0.80 | SMN1; SMN2 (0.34) | — | |
| SCHEMBL31756221 | 0.80 | SMN1; SMN2 (0.34) | — | |
| SCHEMBL34467982 | 0.80 | SMN1; SMN2 (0.34) | — | |
| SCHEMBL34467960 | 0.79 | JAK2 (0.44) | JAK2JAK1CHRNB2CHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260001887-A1 | CYCLIN-DEPENDENT KINASE INHIBITORS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2026-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260001887-A1 | CYCLIN-DEPENDENT KINASE INHIBITORS | CDK4, CCNC, CDK2 | JAK2 565/4885JAK1 755/4885CHRNB2 4010/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.